$STX

MOSLEY WILLIAM D sold $75K of STX

MOSLEY WILLIAM D (CEO) sold 80 shares of Seagate Technology Holdings plc (STX) at $940.00 on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · MOSLEY WILLIAM D
Published Jun 2, 2026, 9:16 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 2, 2026, 9:19 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$STX
Neutral
medium confidence
Mentioned
$STX
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$STXNeutralLow
01

Why it matters

Insider selling can influence short-term sentiment, but 10b5-1 plans are designed to reduce timing-based trading signals.

02

Market read

A disclosed insider sale occurred, but it is pre-arranged and small, limiting tradable fundamental implications.

03

What to watch

The sale size (80 shares) is small and the filing does not indicate any change in company outlook, guidance, or operating performance.

Relevance 6/10Novelty 3/10Timing: Filed after-hours on 2026-06-02; transaction dated 2026-06-01.

Background

SEC Form 4 reports insider transactions; this filing is an open-market sale by the CEO under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$STXNeutralMedium confidence
Context

Seagate CEO William D. Mosley sold $75.2K of STX shares in an open-market transaction under a pre-arranged 10b5-1 plan.

Expected impact

Low likelihood of sustained price impact; any reaction is likely brief unless paired with other company-specific news.

Evidence & confidence

Form 4 shows a small sale size versus typical market moves and explicitly references a pre-arranged 10b5-1 plan, which often reduces interpretive weight.

Market effects

Minimal; insider selling at one storage/tech hardware name rarely changes sector fundamentals.

None indicated beyond potential short-lived sentiment in US trading.

None indicated.

Counterpoint

Even with 10b5-1, repeated insider sales can reflect risk management or diversification rather than bearish views—so the signal may be overstated.

Key entities

  • MOSLEY WILLIAM D

    Seagate CEO and officer/director who sold STX shares.

  • Seagate Technology Holdings plc

    STX issuer; insider sale disclosed via SEC Form 4.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NVDAHighAI 9/10

Markets News, Aug. 27, 2026: Nvidia Stock Powers Higher After Earnings, Driving Tech Gains; Nasdaq Closes Sharply Higher

Nvidia (NVDA) reported strong Q2 earnings and raised Q3 revenue guidance to $108B, driving its stock up 9% and boosting tech sector gains. Nasdaq, S&P 500, and Dow closed higher. Other notable movers include Okta (OKTA) +29%, Salesforce (CRM) +23%, and CrowdStrike (CRWD) +20%. Corporate profits surged $400B in Q2, partly due to $71B in tariff refunds.

$STXMed

Moody’s upgrades Seagate Data rating on AI demand strength

Moody's upgraded Seagate Data's corporate family rating to Ba1 from Ba2, citing AI-driven demand for high-capacity HDDs. The agency expects revenues to grow over 30% annually, reaching $20B, and debt to EBITDA to fall below 0.5x. Seagate faces risks from revenue concentration and pricing pressures. The company had $1.7B in cash and access to a $1.3B credit facility as of July 2026.

$MRNAHighAI 8/10

3 Stocks Soared, 3 Stocks Slumped

Moderna (MRNA) surged 176.97% to $174.38 after reporting positive trial results for a cancer therapy with Merck (MRK). Estee Lauder (EL) rose 16% to $98.01 with revenue up 6.5% Y/Y. MicroStrategy (MSTR) gained 12.68% as Bitcoin prices rose. Nebius (NBIS) fell 10% after a $4.5B convertible note offering. Seagate (STX) dropped 8% to $832.56.

$STXMed

REG - Shield Therapeutics - Shield assumes full control of ACCRUFeR® in the US

Shield Therapeutics (STX) will take full control of ACCRUFeR® in the US from Viatris by September 30, 2026. The deal is expected to boost Shield's profitability and growth, with no upfront payments to Viatris. Shield will pay royalties on US net sales, ranging from high single digits to mid-teens over five years, and retain all gross profits from US sales. The transaction is anticipated to enhance Shield's financial profile and support its path to sustained profitability.